María Fernanda Ramírez

Dr. María Fernanda Ramírez


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2017 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JCJuan Cata
Juan Cata
JVJose F. Velasquez
Jose F. Velasquez
MRMaría Fernanda Ramírez
María Fernanda Ramírez
JVJean-Nicolas Vauthey
Jean-Nicolas Vauthey
Vijaya GottumukkalaVijaya Gottumukkala
Vijaya Gottumukkala
TAThomas Aloia
Thomas Aloia
The magnitude of the perioperative inflammatory response plays a role in surgical outcomes. However, few studies have explored the mechanisms of the resolution of inflammation in the context of surgery. Here, we described the temporal kinetics of interleukin-6, cortisol, lipoxin A4, and resolvin D in patients who underwent oncologic liver resections. All patients gave written informed consent. Demographic and perioperative surgical data were collected, along with blood samples, before surgery and on the mornings of postoperative days 1, 3, and 5. Interleukin-6, cortisol, lipoxin-A4, and resolvin D were measured in plasma. A P value < 0.05 was considered statistically significant. Forty-one patients were included in the study. Liver resection for colorectal metastatic disease was the most commonly performed surgery. The plasma concentrations of interleukin-6 were highest on day 1 after surgery and remained higher than the baseline up to postoperative day 1. Postoperative complications occurred in 14 (24%) patients. Cortisol concentrations spiked on postoperative day 1. The concentrations of lipoxin A4 and resolvin D were lowest on day 1 after surgery. The inflammatory response associated with hepatobiliary surgery is associated with low circulating concentrations of lipoxin A4 and resolvin D that mirror, in an opposite manner, the kinetics of interleukin 6 and cortisol. NCT01438476

8 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
MRMaría Fernanda Ramírez
María Fernanda Ramírez
JCJuan P. Cata
Juan P. Cata
Despite advances in cancer treatments, surgery remains one of the most important therapies for solid tumors. Unfortunately, surgery promotes angiogenesis, shedding of cancer cells into the circulation and suppresses anti-tumor immunity. Together this increases the risk of tumor metastasis, accelerated growth of pre-existing micro-metastasis and cancer recurrence. It was theorized that regional anesthesia could influence long-term outcomes after cancer surgery, however new clinical evidence demonstrates that the anesthesia technique has little influence in oncologic outcomes. Several randomized controlled trials are in progress and may provide a better understanding on how volatile and intravenous hypnotics impact cancer progression. The purpose of this review is to summarize the effect of the anesthesia techniques on the immune system and tumor microenvironment (TME) as well as to summarize the clinical evidence of anesthesia techniques on cancer outcomes.

1 December 2023 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
MRMaría Fernanda Ramírez
María Fernanda Ramírez
ASAmanda Strang
Amanda Strang
GRGavin Roland
Gavin Roland
JLJavier Lasala
Javier Lasala
POPascal Owusu-Agyemang
Pascal Owusu-Agyemang
Cancer-related pain is one of the most common and incapacitating symptoms for cancer patients. Cancer pain can be caused by diagnostic or therapeutic procedures, side effects and toxicity from therapy, or the cancer itself. Uncontrolled cancer-related pain is associated with inadequate quality of life and reduced functional status. Optimal pain management during the perioperative period requires a tailored approach. Interventions that are recommended for the management of acute surgical pain include regional anesthesia, local anesthetic infusions, non-opioid analgesics (ketamine, dexmedetomidine, lidocaine, and non-steroidal anti-inflammatory drugs), and opioids. Despite continued research efforts and advances in cancer treatment, opioids remain the most effective medication to treat moderate to severe cancer-related pain; however, their role has been changing significantly due to the opioid epidemic and opioid misuse. While pre-clinical and retrospective studies have shown a negative association between opioid use and cancer outcomes, randomized control trials have failed to confirm this association. The purpose of this review is to summarize the pharmacological management of acute cancer-related pain during the perioperative period with an emphasis on cancer recurrence.

1 July 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
JVJuan F Villa
Juan F Villa
ASAmanda Strang
Amanda Strang
AOAdebukola Owolabi
Adebukola Owolabi
MRMaría Fernanda Ramírez
María Fernanda Ramírez
Objective: Oral mucositis (OM) is a debilitating complication of cancer therapies, affecting up to 85% of patients undergoing bone marrow transplantation and nearly all receiving head and neck radiotherapy. Characterized by mucosal inflammation, ulceration, and severe pain, OM significantly impairs oral intake, speech, and quality of life. These disruptions, compounded by complications such as infection, bleeding, and increased healthcare costs, often necessitate treatment delays or modifications, negatively impacting cancer prognosis. Recent insights into nociceptive and neuropathic mechanisms of OM-related pain have led to the development of innovative management strategies. Given the debilitating nature of OM in cancer patients and the critical need for effective pain control, this review aims to examine pharmacological advancements targeting the complex nature of OM-related pain, including agents such as lidocaine, doxepin, benzydamine, methylene blue, opioids, gabapentin, palifermin, caphosol, and ketamine. Methods: A literature search was conducted in the PUBMED, COCHRANE, and MEDLINE databases, covering studies from 2000 to 2024. Studies focusing on OM pathogenesis and pain management strategies were screened. Inclusion criteria encompassed randomized controlled trials, meta-analyses, and systematic reviews involving adult patients treated with lidocaine, doxepin, benzydamine, methylene blue, opioids, gabapentin, palifermin, caphosol, or ketamine for OM-associated pain. Conclusion: OM pain arises from nociceptive and neuropathic pathways involving inflammatory cytokines and neuropeptides. Current interventions, including topical and systemic agents, have shown promise, yet variability in treatment protocols and limited high-quality evidence hinder standardized practices. This review highlights the clinical applicability of emerging therapies, such as avasopasem manganese, which has demonstrated efficacy in mitigating OM progression. Ongoing clinical trials targeting novel pathways that modulate mucosal inflammatory response and limit disease severity offer hope for improved pain relief. Addressing the multifaceted nature of OM-associated pain is essential for enhancing quality of life and optimizing cancer treatment outcomes. Further research is needed to establish robust, evidence-based guidelines for OM pain management.

19 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
MRMaría Fernanda Ramírez
María Fernanda Ramírez
JGJuan Jose Guerra-Londono
Juan Jose Guerra-Londono
POPascal Owusu-Agyemang
Pascal Owusu-Agyemang
KFKeith Fournier
Keith Fournier
CGCarlos E. Guerra-Londono
Carlos E. Guerra-Londono
In addition to attaining complete or near complete cytoreduction, the instillation of select heated chemotherapeutic agents into the abdominal cavity has offered a chance for cure or longer survival inpatients with peritoneal surface malignancies. While the heating of chemotherapeutic agents enhances cytotoxicity, the resulting systemic hyperthermia has been associated with an increased risk of severe hyperthermia and its associated complications. Factors that have been associated with an increased risk of severe hyperthermia include intraoperative blood transfusions and longer perfusion duration. However, the development of severe hyperthermia still remains largely unpredictable. Thus, at several institutions, cooling protocols are employed during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Cooling protocols for CRS-HIPEC are not standardized and may be associated with episodes of severe hyperthermia or alternatively hypothermia. In theory, excessive cooling could result in a decreased effectiveness of the intraperitoneal chemotherapeutic agents. This presumption has been supported by a recent study of 214 adults undergoing CRS-HIPEC, where failure to attain a temperature of 38° C at the end of chemo-perfusion was associated with worse survival. Although not statistically significant, failure to maintain a temperature of 38° C for at least 30 minutes was associated with worse survival. Although studies are limited in this regard, the importance of maintaining a steady state of temperature during the hyperthermic phase of intraperitoneal chemotherapy administration cannot be disregarded. The following article describes the processes and physiological mechanisms responsible for hyperthermia during CRS-HIPEC. The challenges associated with temperature management during CRS-HIPEC and methods to avoid severe hypothermia and hyperthermia are also described.

27 August 2021 in Current Opinion in Anaesthesiology
Verified
Journal Article
Closed access
CGCarlos E. Guerra-Londono
Carlos E. Guerra-Londono
DKDaniel Kim
Daniel Kim
MRMaría Fernanda Ramírez
María Fernanda Ramírez
Purpose of review: This review aims to describe the main concerns and controversies of ambulatory surgery in cancer patients while providing an overview of ambulatory cancer anaesthesia. Recent findings: Cancer patients can undergo a variety of ambulatory surgeries. The introduction of robotic approach and the implementation of enhanced recovery programmes have allowed patients to avoid hospital admissions after more complex or invasive surgeries. In this context, the anaesthesiologist plays a key role in ensuring that the ambulatory surgical centre or the hospital-based ambulatory department is equipped for the perioperative challenges of the cancer population. Cancer patients tend to be older and with more comorbidities than the general population. In addition, these individuals may suffer from chronic conditions solely because of the cancer itself, or the treatment. Consequently, frailty is not uncommon and should be screened on a routine basis. Regional analgesia plays a key role in the provision of opioid-sparing multimodal analgesia. Summary: Neither regional anaesthesia or general anaesthesia have proven to affect the long-term oncological outcomes of cancer patients undergoing ambulatory surgery. In addition, there is insufficient evidence to suggest the use of total intravenous anaesthesia or inhalational anaesthesia over the other to decrease cancer recurrence.